Quantcast

Latest Dasatinib Stories

2014-07-15 12:29:21

The Upcoming Entry of New Generation TKIs will Challenge the Established Position of CML Treatments in Brazil and Mexico, According to Findings from Decision Resources Group BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that, despite the fact that the treatment armamentarium for chronic myeloid leukemia (CML) in Brazil and Mexico includes all three tyrosine kinase inhibitors (TKIs)--Novartis' Glivec (imatinib), Bristol-Myers Squibb's Sprycel (dasatinib) and...

2014-07-01 16:25:46

LONDON, July 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Bristol-Myers Squibb Company - Product Pipeline Review - 2014http://www.reportbuyer.com/pharma_healthcare/therapeutic/bristol_myers_squibb_company_product_pipeline_review_2013.html Bristol-Myers Squibb Company - Product Pipeline Review - 2014 SummaryGlobal Markets Direct's, 'Bristol-Myers Squibb Company - Product Pipeline Review - 2014', provides an overview of the Bristol-Myers Squibb...

2014-06-02 12:28:29

High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed hematologists in China estimate that Novartis's Glivec (imatinib) will lose nearly half of its patient share for treatment of chronic myeloid leukemia (CML) in the next three years, due to the market entry of generic imatinib. Nevertheless,...

2014-05-27 12:32:14

Robust Value Dossiers and Smart Uptake Strategies are Vital to Secure Optimal Market Access in Europe, According to Findings from Decision Resources Group BURLINGTON, Mass., May 27, 2014 /PRNewswire/ -- Decision Resources Group finds that Novartis's Glivec is the clear agent of choice for first-line treatment of chronic myelogenous leukemia (CML) patients in the chronic phase, according to surveyed hematological oncologists from France, Germany, Italy, Spain and the United Kingdom (EU5). Use...

2014-01-09 08:28:38

LONDON, Jan. 9, 2014 /PRNewswire/ -- The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer's BOSULIF(®) (bosutinib). The trial, which will be conducted across multiple sites in the United States, Asia and Europe, will evaluate BOSULIF, administered at a starting dose level of 400 mg daily, as a...

2013-03-21 14:58:25

Researchers at Moffitt Cancer Center have completed a phase II clinical trial to determine the safety and efficacy of dasatinib for patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, or acute myeloid leukemia resulting from MDS and have failed treatment with azanucleosides. The therapy may not be effective for all patients, but those with trisomy 8 chromosomal disorder have higher rates of stable disease and respond better to treatment with dasatinib,...

2012-11-29 14:56:43

HOUSTON — A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine. All 12 patients in the trial with chronic phase CML and the T315I mutation had a complete hematologic response (absence of CML cells in the blood) after treatment with ponatinib. Eleven had a major reduction in CML cells in the bone marrow and nine achieved a...

2012-08-13 22:03:30

Discovery of the genetic basis of a high-risk subtype of leukemia shows some patients might benefit from existing targeted therapies, advancing the goal of curing all children with the most common childhood cancer Scientists have identified new genetic alterations underlying a high-risk subtype of the most common childhood cancer that could be effectively targeted with existing leukemia therapies. The study focused on a subtype of acute lymphoblastic leukemia (ALL) known as Philadelphia...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related